Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas.

Kummar, Shivaani; Gutierrez, Martin E; Maurer, Barry J; Reynolds, C Patrick; Kang, Min; Singh, Hardeep; Crandon, Sonja; Murgo, Anthony J; Doroshow, James H

Kummar, Shivaani; Gutierrez, Martin E; Maurer, Barry J; Reynolds, C Patrick; Kang, Min; Singh, Hardeep; Crandon, Sonja; Murgo, Anthony J; Doroshow, James H.

Affiliation

Kummar S; National Cancer Institute, Building 31, Room 3A44, 31 Center Drive, National Institutes of Health, Bethesda, MD 20892, USA.

Anticancer Res ; 31(3): 961-6, 2011 Mar.

Article in En | MEDLINE | ID: mdl-21498721

Subject(s)

Antineoplastic Agents/administration & dosage; Antineoplastic Agents/therapeutic use; Fenretinide/administration & dosage; Fenretinide/therapeutic use; Lipids/chemistry; Lymphoma/drug therapy; Administration, Oral; Adult; Aged; Antineoplastic Agents/adverse effects; Antineoplastic Agents/pharmacokinetics; Dose-Response Relationship, Drug; Female; Fenretinide/adverse effects; Fenretinide/pharmacokinetics; Humans; Lymphoma/blood; Male; Middle Aged; Powders

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Fenretinide / Lipids / Lymphoma / Antineoplastic Agents Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Anticancer Res Year: 2011 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google